Rockefeller Capital Management
HQL

Rockefeller Capital Management’s abrdn Life Sciences Investors HQL Stock Holding History

Rockefeller Capital Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$602 Buy
+37
New +$618 ﹤0.01% 4549
2025
Q4 		– Sell
-642
Closed -$9.96K – 4742
2025
Q3 		$9.96K Buy
+642
New +$8.79K ﹤0.01% 3646

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rockefeller Capital Management's HQL Position: Q1 2026 in Review

Rockefeller Capital Management opened a new position in abrdn Life Sciences Investors (HQL) in Q1 2026: 37 shares worth $602. The stake represents ﹤0.01% of the portfolio and ranks #4549 among its holdings. This is a return to the name: Rockefeller Capital Management previously reported a position in HQL as recently as Q3 2025.

Rockefeller Capital Management first reported a position in HQL in Q3 2025 and has held it in 2 quarters since. The position peaked at $9.96K in Q3 2025. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • Rockefeller Capital Management held 37 shares of abrdn Life Sciences Investors worth $602 as of Q1 2026.
  • abrdn Life Sciences Investors was a new Rockefeller Capital Management position in Q1 2026.
  • abrdn Life Sciences Investors made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4549 holding.
  • Rockefeller Capital Management first reported a position in abrdn Life Sciences Investors in Q3 2025 and has held it in 2 quarters since.
  • Rockefeller Capital Management's abrdn Life Sciences Investors position peaked at $9.96K in Q3 2025.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.